Riskpilot← Back to searchSign inGet full accessKARO PHARMA AS
ASActiveOrg 917296200Østensjøveien 27, 0661 OsloWholesale of pharmaceutical and medical goods · NACE 4646Est. 194023 employeeswww.karopharma.com
Revenue 2024
NOK 714,3M
+3% vs 2023
EBITDA margin
25.8%
+10% vs 2023
Equity ratio
40.4%
Financial strength
Net profit 2024
NOK 146,3M
+16% vs 2023
| Revenue | NOK 714,3M | +3% |
| EBITDA | NOK 184M | +10% |
| Net profit | NOK 146,3M | +16% |
| Total assets | NOK 502,2M | +12% |
| Equity | NOK 202,8M | +34% |
| Employees | 23 | — |
Legal name
KARO PHARMA AS
Org number
917296200
Legal form
Aksjeselskap
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
31. januar 1940
Share capital
—
Employees
23 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
To styremedlemmer i fellesskap.
Address
Østensjøveien 27, 0661 Oslo
Website
www.karopharma.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 557 199 | 439 970 | 399 738 | 396 949 | 459 967 | 443 050 | 425 492 | 529 516 | 641 458 | 692 096 | 714 301 |
| Staff expenses | −144 093 | −92 832 | −44 247 | −52 199 | −26 863 | −28 616 | −31 614 | −29 910 | −30 968 | −36 306 | −34 169 |
| EBITDA | 95 391 | 70 146 | 88 060 | 75 904 | 130 290 | 108 167 | 117 299 | 147 845 | 136 072 | 167 521 | 183 961 |
| Depreciation & amort. | −111 213 | −2 577 | −205 | −1 049 | −11 959 | −34 487 | −4 886 | −4 086 | −6 097 | −4 299 | −4 416 |
| EBIT | −15 823 | 67 569 | 87 855 | 74 855 | 118 331 | 73 680 | 112 413 | 143 759 | 129 975 | 163 222 | 179 544 |
| Net financials | −5 323 | −6 688 | 74 | −256 | 46 | 447 | −4 709 | −3 817 | −3 774 | −1 794 | 7 968 |
| Profit before tax | −21 146 | 60 881 | 87 929 | 74 599 | 118 377 | 74 127 | 107 704 | 139 942 | 126 201 | 161 427 | 187 512 |
| Tax | −5 686 | 18 730 | 24 320 | 19 289 | 27 961 | 16 352 | 23 732 | 30 791 | 27 769 | 35 521 | 41 211 |
| Net profit | −15 460 | 42 151 | 63 609 | 55 310 | 90 416 | 57 775 | 83 972 | 109 151 | 98 432 | 125 906 | 146 301 |
| Item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 346 978 | 193 204 | 294 879 | 249 593 | 297 064 | 301 262 | 282 382 | 378 532 | 381 062 | 449 565 | 502 230 |
| Equity | 66 608 | 85 827 | 89 934 | 116 723 | 126 286 | 132 577 | 131 169 | 152 743 | 148 287 | 151 038 | 202 785 |
| Long-term debt | 75 000 | 4 625 | 54 950 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 188 613 | 96 360 | 144 576 | 128 629 | 167 894 | 166 124 | 148 571 | 222 926 | 232 775 | 298 527 | 299 445 |
| Total debt | 263 613 | 100 985 | 199 526 | 128 629 | 167 894 | 166 124 | 148 571 | 222 926 | 232 775 | 298 527 | 299 445 |
EBITDA margin
25.8%
This company
15.8%
Market median
+63% vs market
20142024
Equity ratio
40.4%
This company
38.2%
Market median
+6% vs market
20142024
Return on equity
72.1%
This company
18.4%
Market median
+292% vs market
20142024
Net profit margin
20.5%
This company
8.1%
Market median
+153% vs market
20142024
Asset turnover
1.42×
This company
1.12×
Market median
+27% vs market
20142024
Debt / equity
1.48×
This company
0.62×
Market median
-139% vs market
20142024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Brønnøysundsregistrene · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via Brønnøysundsregistrene · Period 2014-01-01 – 2014-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
TL Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
ET Chief Executive Officer | Chief Executive Officer | 2025 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2020 | — | — | |
| Chairman | 2021 | — | — | |
| Board of Directors | 2025 | — | — | |
| Board of Directors | 2025 | — | — | |
| Board of Directors | 2021 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Karo Healthcare Norge As | Company | 100.0% | 100.0% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Karo Healthcare Norge As
KARO PHARMA AS Board members of KARO PHARMA AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Thor Linge | Chief Executive Officer | 0 companies |
| Esad Toric | Chief Executive Officer | 0 companies |
| Lars Magnus Nylen | Board of Directors | 0 companies |
| Christoffer Erik Mathies Lorentzen | Chairman | 0 companies |
| Egil Mølsted Madsen | Board of Directors | 0 companies |
| Synnøve Elisabeth With Notø | Board of Directors | 0 companies |
| Jon Sebastian Jonsson | Board of Directors | 0 companies |